Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor for relapsed or refractory PTCL/CTCL
ACTRN12614001328662Phase 2Terminated
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selinexor in peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL), sponsored by Karyopharm Therapeutics Inc. Primary endpoint: Overall disease response rate. Started Mar 2015; status: terminated.
02
Drugs
selinexor
03
Conditions
peripheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on ACTRN12614001328662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614001328662.